Monitor for future insider buying or selling patterns from the new CFO, which could signal confidence in the company's prospects. The option grant itself is routine and not a trading signal.
Price Chart
Executive Summary
Alexander Duke Schwartz filed a Form 3 initial statement of beneficial ownership upon becoming CFO of Retension Pharmaceuticals, disclosing a grant of 64,413 stock options exercisable at $2.43 per share, vesting over four years. This is a routine insider filing with no material financial impact.
Key Facts
- Alexander Duke Schwartz appointed as Chief Financial Officer of Retension Pharmaceuticals
- Received 64,413 stock options with exercise price of $2.43 per share
- Options vest 25% on first anniversary, then 1/36 monthly thereafter
- Options expire on April 30, 2036
Financial Impact
No immediate financial impact; option grant is standard compensation for a new officer
Risk Factors
- No financial data in filing to assess company performance
- Option grant is standard compensation, not indicative of near-term catalysts
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001213900-26-108141 |
| Document: 0001213900-26-108141-index.html | 0001213900-26-108141 |
| Document: 0001213900-26-108141.txt | 0001213900-26-108141 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 3d ago | 8-K | $16.55 | awaiting T+5 | — | $14.55 (−12.11%) |
Oct 16, 2026 9d ago | SC 13G | $16.33 | awaiting T+5 | — | $14.55 (−10.93%) |
Oct 16, 2026 10d ago | SC 13G | $14.07 $15.25 | ▲ +8.39% | ▲ +8.82% | $14.55 (+3.38%) |
Oct 15, 2026 11d ago | SC 13G | $12.21 $15.50 | ▲ +26.95% | ▲ +27.96% | $14.55 (+19.12%) |
Oct 14, 2026 11d ago | SC 13D | $12.21 $15.50 | ▲ +26.95% | ▲ +27.96% | $14.55 (+19.12%) |
Oct 13, 2026 12d ago | Insider Cluster | $11.64 $15.00 | ▲ +28.87% | ▲ +28.41% | $14.55 (+24.96%) |
Oct 13, 2026 12d ago | 3 | $11.64 $15.00 | ▲ +28.87% | ▲ +28.41% | $14.55 (+24.96%) |
Oct 9, 2026 16d ago | 424B4 | $11.32 $16.33 | ▲ +44.26% | ▲ +45.75% | $14.55 (+28.49%) |
Oct 9, 2026 17d ago | EFFECT | $10.53 $14.07 | ▲ +33.62% | ▲ +35.59% | $14.55 (+38.13%) |
Oct 8, 2026 17d ago | 3 | $10.53 $14.07 | ▲ +33.62% | ▲ +35.59% | $14.55 (+38.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers